BNC Korea Co., Ltd. (256840.KQ)
KRW 4160.0
(-1.42%)
KRW 4160.0
(-1.42%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 10.81 Billion KRW | 159.88% |
| 2022 | -10.09 Billion KRW | 10.13% |
| 2021 | -11.23 Billion KRW | -1285.26% |
| 2020 | 947.85 Million KRW | -60.85% |
| 2019 | 2.42 Billion KRW | -44.09% |
| 2018 | 4.33 Billion KRW | 10352.91% |
| 2017 | -42.23 Million KRW | -151.77% |
| 2016 | -16.77 Million KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 4.44 Billion KRW | 292.18% |
| 2024 Q1 | 1.13 Billion KRW | 2.91% |
| 2023 FY | 6.04 Billion KRW | 159.88% |
| 2023 Q3 | 3.66 Billion KRW | 3.26% |
| 2023 Q4 | 1.1 Billion KRW | -69.96% |
| 2023 Q1 | -2.27 Billion KRW | 8.95% |
| 2023 Q2 | 3.54 Billion KRW | 256.36% |
| 2022 Q2 | -3.45 Billion KRW | -64.14% |
| 2022 FY | -10.09 Billion KRW | 10.13% |
| 2022 Q4 | -2.49 Billion KRW | -15.3% |
| 2022 Q3 | -2.16 Billion KRW | 37.46% |
| 2022 Q1 | -2.1 Billion KRW | 14.0% |
| 2021 FY | -11.23 Billion KRW | -1285.26% |
| 2021 Q3 | -1.86 Billion KRW | 0.0% |
| 2021 Q4 | -2.44 Billion KRW | -31.65% |
| 2020 FY | 947.85 Million KRW | -60.85% |
| 2019 FY | 2.42 Billion KRW | -44.09% |
| 2018 FY | 4.33 Billion KRW | 10352.91% |
| 2017 FY | -42.23 Million KRW | -151.77% |
| 2016 FY | -16.77 Million KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | -19.54 Billion KRW | 155.361% |
| CMG Pharmaceutical Co., Ltd. | 5.72 Billion KRW | -88.966% |
| Celltrion Pharm, Inc. | 36.07 Billion KRW | 70.007% |
| Huons Global Co., Ltd. | 122.92 Billion KRW | 91.199% |
| DongKook Pharmaceutical Co., Ltd. | 66.87 Billion KRW | 83.822% |
| Enzychem Lifesciences Corporation | -14.35 Billion KRW | 175.359% |
| Humedix Co., Ltd. | 37.31 Billion KRW | 71.003% |
| Boditech Med Inc. | 33.44 Billion KRW | 67.65% |
| EuBiologics Co., Ltd. | 7.69 Billion KRW | -40.519% |
| FutureChem Co.,Ltd | -8.4 Billion KRW | 228.673% |
| Huons Co., Ltd. | 59.79 Billion KRW | 81.907% |
| AptaBio Therapeutics Inc. | -16.37 Billion KRW | 166.074% |